CVS Caremark GLP-1 Coverage 2026: Wegovy, Zepbound, Foundayo
CVS Caremark GLP-1 coverage in late 2026 looks like this: Wegovy (shot and pill) and Zepbound are both preferred on Caremark's standard commercial drug lists, and Foundayo can be covered if your plan allows it. Your employer or union still decides whether weight loss drugs are covered at all, and prior approval is common. On November 14, 2026, CVS said the drugs pay for themselves when they cost a plan less than $350 a month. If you are on one of these drugs, Sharpy helps you keep muscle with one protein target and one 20-minute workout a day.
Does CVS Caremark cover GLP-1 drugs in 2026? Often yes, but it depends on your plan. Caremark's standard commercial drug lists now prefer Wegovy (shot and pill) and Zepbound for weight loss. Foundayo is open to plans that want it. Your employer or union still chooses whether weight loss drugs are covered at all.
There is also fresh news. On November 14, 2026, CVS Health said GLP-1 drugs pay for themselves when a plan pays less than $350 a month for them. That number matters for anyone worried their coverage will be cut in 2027.
What GLP-1 is covered by Caremark in 2026?
Caremark is the pharmacy benefit manager owned by CVS Health. It builds template drug lists, called formularies, that employers and health plans can adopt. Here is where the weight loss drugs stand on the standard commercial lists.
| Drug | Status on Caremark standard commercial lists | Since |
|---|---|---|
| Wegovy injection (semaglutide) | Preferred | July 1, 2025 |
| Wegovy pill (semaglutide) | Preferred | Kept preferred status in 2026 |
| Zepbound (tirzepatide) | Preferred again, after being dropped on July 1, 2025 | October 1, 2026 |
| Foundayo (orforglipron) | New-drug block removed. Covered if the plan sponsor chooses | June 1, 2026 |
CVS announced these changes on May 28, 2026. The Boston Globe reported that the standard commercial template covers roughly 25 to 30 million Americans. CVS spokesman Philip Blando told the paper that Wegovy and Zepbound would have the same copay. The exact copay is set by each employer or union.
Diabetes drugs such as Ozempic and Mounjaro are a separate question. The 2026 announcement was about weight loss drugs. If you have type 2 diabetes, look up your drug in your plan's list.
Why did Caremark drop Zepbound, then bring it back?
In May 2025, Caremark said it would make Wegovy its preferred weight loss drug and remove Zepbound from its standard lists. The change took effect on July 1, 2025. Many people on Zepbound had to switch or pay cash.
The effect was large. A Truveta analysis of 700,907 patients, cited by Managed Healthcare Executive, found that monthly switching away from tirzepatide jumped from about 0.6% to 10.2% in June and July 2025. Patients sued, and the Boston Globe described the 2026 reversal as coming "after backlash from patients."
CVS says the hard line saved money. Blando told the Globe that the company estimates it generated 10 to 15 percent of extra savings across the drug class for its clients. If you switched and want to compare the two drugs, see Wegovy HD vs Zepbound.
Does CVS Caremark cover GLP-1 for weight loss on my plan?
A drug being "preferred" does not mean your plan pays for it. Three things decide that.
- Your plan sponsor. Employers can adopt the template, exclude weight loss drugs, or add their own rules. KFF's 2025 survey found that about one in five firms with 200 or more workers covered GLP-1s for weight loss. Among firms with 5,000 or more workers it was 43%.
- Your plan year. Some employers only change benefits on January 1. The October 1, 2026 Zepbound change may reach you later.
- Prior approval. Most plans that cover these drugs want paperwork first.
To check, sign in to your Caremark account and look up the drug, or call the number on your member ID card. Ask three questions: Is the drug covered for weight loss? Does it need prior authorization? What will my copay be?
Coverage is under pressure. Reuters reports that about 14% of companies have dropped or plan to drop obesity GLP-1 coverage in 2027. Our guide on insurance dropping GLP-1 coverage explains what to do if yours is one of them.
How does CVS Caremark GLP-1 prior authorization work?
There is no form for you to fill out. Prior authorization is a request your prescriber sends to Caremark. It usually includes your diagnosis, your weight and height, weight-related health problems, and what you have tried before.
Criteria differ from plan to plan. We could not read Caremark's own criteria documents for this guide, so we will not guess at them. Many plans follow the FDA labels, which approve Wegovy and Zepbound for adults with obesity, or with overweight plus at least one weight-related condition, along with diet and exercise. Plans often add their own rules, such as a weight loss check before a renewal.
What you can do:
- Ask your prescriber's office to start the request, and give them your Caremark member ID.
- Ask the plan for its written criteria for your drug.
- Keep your own record of your starting weight and your weight now.
- If you are denied, ask for the reason in writing and appeal. Our Zepbound appeal letter guide has a checklist that works for other GLP-1s too.
Many plans want proof that the drug is working and that you are doing your part with food and exercise. A daily log helps. Sharpy gives you one protein target, one 20-minute workout and one Shape Score a day, so you have a simple record of your habits to show your doctor.
What did CVS say about the $350 a month price?
Reuters reported the new analysis on November 14, 2026. CVS looked at claims from its Aetna insurance business. It compared people who started Ozempic, Mounjaro, Wegovy or Zepbound between 2023 and 2025 with similar people who did not.
| Finding | Number |
|---|---|
| Emergency room visits in years 1 and 2 | 10% to 12% lower |
| Hospital stays among 4,000 people still on the drug at 3 years | 34% to 42% lower |
| Medical savings over 3 years, per person | $9,400 |
| Extra drug spending over 3 years, per person | $13,300 |
| Net extra cost over 3 years, per person | $3,900 |
| Price where a plan breaks even | Under $350 a month |
| What plans pay now (2025 EBRI study) | $617 to $766 a month |
By our math, that $3,900 gap works out to about $108 a month per person. So at today's prices, plans still lose money on the drugs. At less than $350 a month, CVS says they would break even.
Dr. Amy Compton-Phillips, the chief medical officer at CVS Health, told Reuters: "I hope that we can reach that price sooner rather than later." She also said: "The higher-risk the person is, the quicker you get to a return on investment."
Two limits are worth knowing. The analysis mixed people with diabetes, obesity and other conditions, and it did not break out obesity alone. It also comes from CVS itself, which negotiates drug prices. Reuters did not name a published paper. CVS planned to present the findings at the HLTH conference on November 15, 2026.
What this means for your coverage
The analysis does not change your plan today. It does give employers a reason to keep coverage if prices fall. Cash prices already sit near the break-even line. Reuters put them at about $299 a month for Zepbound and $349 for Wegovy.
It also shows what plans care about: fewer hospital and ER visits over time. Those gains showed up in people who stayed on treatment for years.
What if your Caremark plan does not cover it?
You still have options.
- Manufacturer savings cards. If you have commercial insurance that covers the drug, CVS says the cost can be as low as $25 a month with a manufacturer coupon.
- Self-pay programs. LillyDirect sells Zepbound and Foundayo for cash. NovoCare does the same for Wegovy.
- CVS cash options. In August 2026, CVS said some drugs and doses can cost as little as $149 without insurance when you use a manufacturer voucher. It also launched a $29 online MinuteClinic weight loss visit for self-paying adults ages 18 to 64.
- Medicare. The Medicare GLP-1 Bridge offers certain GLP-1s for $50 a month to eligible people through December 31, 2027.
Do not stretch, split or skip doses to save money. Talk to your prescriber about a plan you can afford.
The bottom line
CVS Caremark's standard lists now prefer both Wegovy and Zepbound, and Foundayo is open to plans that want it. Whether you are covered still comes down to your employer and a prior approval. CVS's own numbers say the drugs make financial sense for plans below $350 a month, which is a good sign for future coverage, but not a promise.
However you pay for it, make the drug count. Lose fat, keep muscle. Sharpy keeps that simple with one protein target, one short workout and one Shape Score each day.
Sources
- Reuters, November 14, 2026: CVS says GLP-1s save money when priced below $350 per month (via Investing.com)
- Managed Healthcare Executive, May 28, 2026: CVS Caremark to put Zepbound back on formulary and add Foundayo
- Pharmaceutical Commerce, May 29, 2026: CVS Caremark Expands GLP-1 Formulary Coverage
- Boston Globe, May 29, 2026: CVS restores coverage of Zepbound
- CVS Health, August 5, 2026: CVS Health enhances its direct-to-consumer weight management offerings
- DailyMed: Wegovy and Zepbound prescribing information
Questions people ask
Does CVS Caremark cover GLP-1 drugs for weight loss?
It can, but your plan sponsor decides. Caremark keeps template drug lists, and since October 1, 2026 its standard commercial list has Wegovy and Zepbound as preferred weight loss options. Your employer, union or health plan chooses whether to cover weight loss drugs at all and what rules apply. Check your own plan before you assume a yes or a no.
What GLP-1 is covered by Caremark in 2026?
For weight loss, the preferred drugs on the standard commercial lists are Wegovy injection, the Wegovy pill and Zepbound. Foundayo, the Lilly pill, has been open to plans that choose to cover it since June 1, 2026. Diabetes GLP-1s follow separate rules, so check your plan drug list for those.
Will CVS Caremark cover Wegovy?
Wegovy has been the preferred weight loss GLP-1 on Caremark standard lists since July 1, 2025, and both the shot and the pill kept that status in 2026. You still need a plan that covers weight loss drugs, and most plans ask for prior approval first.
Is Zepbound covered by CVS Caremark again?
Yes, on the standard commercial lists. Caremark dropped Zepbound on July 1, 2025 and added it back as a preferred option on October 1, 2026. A CVS spokesman told the Boston Globe that Wegovy and Zepbound would have the same copay. Some employers only change benefits at the start of a plan year, so ask yours when the change applies.
Is there a CVS Caremark GLP-1 prior authorization form I can fill out?
Not as a patient. Prior authorization is a request your prescriber sends to Caremark with your diagnosis and history. Your part is to ask the office to start it, give them your Caremark member ID and follow up. If it is denied, you and your prescriber can appeal.
Does Aetna use CVS Caremark for GLP-1 coverage?
Aetna and Caremark are both owned by CVS Health, and Caremark manages pharmacy benefits for many Aetna plans. Each plan still has its own drug list and rules. Look up the drug in your Aetna or Caremark account, or call the number on your member ID card.
How much do GLP-1 drugs cost at CVS without insurance?
Reuters reported cash prices of about $299 a month for Zepbound and $349 for Wegovy as of November 2026. CVS said in August 2026 that some drugs and doses can be as low as $149 with a manufacturer voucher. Prices depend on the drug and the dose, so ask the pharmacy for your exact price.